Drug repositioning

Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the application of known drugs and compounds to treat a different disease.[1]

Smaller companies, including NovaLead Pharma,Ore Pharmaceuticals, Biovista, Numedicus, Melior Discovery and SOM Biotech are also performing drug repositioning on a systematic basis.[1][2] These companies use a combination of approaches including in silico biology and in vivo/in vitro experimentation to assess a compound and develop and confirm hypotheses concerning its usage for new indications.

Using drug repositioning, pharmaceutical companies have achieved a number of successes; for example, Pfizer's Viagra for erectile dysfunction and Celgene's thalidomide for cancer.[3][4]

See also

References

  1. 1 2 Sleigh SH, Barton CL (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811.
  2. ↑ "Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review". Drug Discovery World. Retrieved 1 May 2015.
  3. ↑ Ashburn TT, Thor KB (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–83. doi:10.1038/nrd1468. PMID 15286734.
  4. ↑ Institute of Medicine (2014). Drug Repurposing and Repositioning: Workshop Summary. National Academies Press. ISBN 978-0-309-30204-3.

Further reading

  • Chong CR, Sullivan DJ (August 2007). "New uses for old drugs". Nature. 448 (7154): 645–6. doi:10.1038/448645a. PMID 17687303.
  • Tartaglia LA (November 2006). "Complementary new approaches enable repositioning of failed drug candidates". Expert Opinion on Investigational Drugs. 15 (11): 1295–8. doi:10.1517/13543784.15.11.1295. PMID 17040191.
  • Aronson JK (November 2007). "Old drugs--new uses". British Journal of Clinical Pharmacology. 64 (5): 563–5. doi:10.1111/j.1365-2125.2007.03058.x. PMC 2203255. PMID 17935601.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.